



Telmisartan & Metoprolol Succinate Prolonged-Release Tablets

Telklein-Beta

Product Overview

Product Name: **Telklein-Beta**

Formulation: Telmisartan & Metoprolol Succinate Prolonged-Release Tablets

Strength: Telmisartan 40 mg + Metoprolol Succinate Prolonged Release 25 mg

Dosage Form: Tablets

Composition per Tablet

Each prolonged-release film-coated tablet contains:

- Telmisartan IP ... 40 mg
- Metoprolol Succinate Prolonged Release IP ... 25 mg
- Excipients ... q.s.

DESCRIPTION

Telklein-Beta is a fixed-dose combination of Telmisartan and Metoprolol Succinate Prolonged Release indicated for the management of hypertension (high blood pressure). Telmisartan is an angiotensin II receptor blocker (ARB) that relaxes blood vessels by blocking the action of angiotensin II, thereby lowering blood pressure. Metoprolol Succinate is a selective β_1 -adrenergic receptor blocker that slows the heart rate, reduces cardiac workload, and lowers blood pressure. Together, they provide effective and sustained blood pressure control while helping reduce the risk of cardiovascular complications.

INDICATIONS:

Used in the management of:

- Essential hypertension (high blood pressure)
- Patients whose blood pressure is not adequately controlled with single-agent therapy
- Reduction of cardiovascular risk in hypertensive patients, as advised by the physician
- Long-term blood pressure management



Dosage & Administration

Adults:

One tablet once daily or as directed by the physician.

The tablet should be swallowed whole with water and should not be crushed or chewed. It may be taken with or without food, preferably at the same time each day.

Do not exceed the recommended dosage without medical supervision.

CONTRAINDICATIONS

- Hypersensitivity to Telmisartan, Metoprolol, other beta-blockers, or any component of the formulation.
- Severe bradycardia (slow heart rate).
- Second- or third-degree atrioventricular (AV) block without a functioning pacemaker.
- Cardiogenic shock.
- Decompensated heart failure.
- Severe hepatic impairment.

PRECAUTIONS

- Monitor blood pressure and heart rate regularly during treatment.
- Use with caution in patients with renal or hepatic impairment.
- Do not discontinue therapy abruptly without medical advice.
- Use cautiously in patients with diabetes mellitus, bronchial asthma, chronic obstructive pulmonary disease (COPD), or peripheral vascular disease.
- Monitor serum potassium and renal function periodically.
- Use during pregnancy and lactation only if clearly recommended by the physician.

SIDE EFFECTS

Common:

- Dizziness.
- Fatigue.
- Headache.
- Slow heart rate (bradycardia).
- Low blood pressure (hypotension).
- Cold hands and feet.



RARE:

- Worsening heart failure.
- Bronchospasm in susceptible patients.
- Hyperkalemia.
- Allergic reactions including rash or angioedema.
- Impaired kidney function.

STORAGE INSTRUCTIONS

Store in a cool, dry place below 25°C.
Protect from direct sunlight and moisture.
Keep out of reach of children.

PRESENTATION

Alu Alu pack containing 10 × 10 tablets.

SCHEDULE

Schedule H Prescription Drug – To be sold by retail on the prescription of a Registered Medical Practitioner only.

***Warning: * Schedule H drug** – Not to be sold by retail without the prescription of a Registered Medical Practitioner.

Made in India for:



H.no:1-2, GaneshNagarColony, Kuntloor, Hayathnagar
R.R.Dist, Telangana, 501505.